论文信息 - Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. - 字舞流文

Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

J. Lunceford | E. Winer | J. Mejia | V. Karantza | P. Jelinic | R. Cristescu | S. Im | P. Schmid | S. Ohtani | J. Cortés | A. Gonçalves | E. Muñoz-Couselo | O. Lipatov | I. Witzel | K. Lee | D. Aurora-Garg | L. Testa | Lingkang Huang | J. A. Mejia